Pfizer, Inc.

PFE | News 4 | $26.27 -0.19% -0.15% 23M

(0.0% 1d) (-4.0% 1m) (-33.1% 1y) (0.0% 2d) (0.2% 3d) (1.2% 7d) (-31.9% volume)
Earnings Calendar: 2024-01-30
Market Cap: $ 148,754,959,715
http://www.pfizer.com
Sec Filling | Patents | 88300 employees

(US) Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

vaccine immunology brands injection

Drugs

Flector (Diclofenac Epolamine)
FLECTOR (Diclofenac Epolamine)

add to watch list Paper trade email alert is off

Press-releases

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M

Health Technology

| 1.23% | O: 0.0% H: 1.92% C: 1.0%
emblaveo treatment for infections

Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M

Health Technology

| 0.0% | O: 0.11% H: 0.38% C: -0.04%
meeting

NIIMBL Announces $10M for 8 New Biopharmaceutical Manufacturing Projects
Published: 2024-04-09 (Crawled : 18:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M

Health Technology

| -1.72% | O: -0.97% H: 0.26% C: -0.75%
for

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M

Health Technology

| -0.88% | O: 0.73% H: 2.49% C: 0.11%
abrysvo disease positive risk for rsv results study

ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager
Published: 2024-04-08 (Crawled : 17:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M

Health Technology

| -1.28% | O: -0.39% H: 0.0% C: 0.0%
DOW | $56.98 0.42% 0.0% 5M

Process Industries

| -4.94% | O: 0.44% H: 0.4% C: -0.72%
dean

ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
Published: 2024-04-08 (Crawled : 13:30) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M

Health Technology

| -1.28% | O: -0.39% H: 0.0% C: 0.0%
fda approval for hiv living

Bluerock Value Exchange Fully Subscribes $46.5 Million Diversified Industrial Portfolio I DST
Published: 2024-03-27 (Crawled : 13:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M

Health Technology

| -4.6% | O: 0.43% H: 0.81% C: 0.25%
million

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
Published: 2024-03-26 (Crawled : 21:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M

Health Technology

| -4.6% | O: 0.43% H: 0.81% C: 0.25%
therapeutics

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M

Health Technology

| -5.05% | O: -0.18% H: 0.4% C: -0.14%
pharmaceuticals

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Published: 2024-03-18 (Crawled : 21:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M

Health Technology

| -5.05% | O: -0.18% H: 0.4% C: -0.14%
ARVN | $32.51 -4.38% -4.58% 470K

Health Technology

| -20.19% | O: -3.22% H: 4.58% C: 3.23%
medical

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001225208-24-005065	4	2024-04-16	2024-04-15	Buy	A	54	27864
0001225208-24-005064	4	2024-04-16	2024-04-15	Buy	A	20	659636
0001225208-24-005034	4	2024-04-11	2024-04-10	Buy	A	108	27806
0001225208-24-005033	4	2024-04-11	2024-04-10	Buy	A	18	659517